Finance

Lists
Why is CBIO up 3.48%?
Dive Deeper
CBIO:NASDAQ
Crescent Biopharma Inc
$13.96
+3.48%
(+0.47) 1D
Oct 8, 1:19:05 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CBIO...
Open
$13.39
High
$14.01
Low
$12.98
Mkt. cap
518.53M
Avg. vol.
494.38K
Volume
53.18K
52-wk high
$27.41
52-wk low
$8.72
EPS
-$7.41
Beta
1.27
Shares outstanding
37.14M
No. of employees
69
Open
$13.39
High
$14.01
Low
$12.98
Mkt. cap
518.53M
Avg. vol.
494.38K
Volume
53.18K
52-wk high
$27.41
52-wk low
$8.72
EPS
-$7.41
Beta
1.27
Shares outstanding
37.14M
No. of employees
69
News stories
From web sources and news partners
About Crescent Biopharma Inc
CEO-
Employees69
Founded2024
HeadquartersWaltham, Massachusetts, United States
SectorBiotechnology
Websitecrescentbiopharma.com
Analyst ratings
Based on 4 analysts giving stock ratings to CBIO in the past 3 months
Strong buy
Buy
4
Hold
0
Sell
0
12-month forecast
Based on 4 Wall Street analysts offering 12 month price targets for CBIO in the last 3 months.
Highest
Current $13.96
$36.00 (+157.88%)
Average
$29.75 (+113.11%)
Lowest
$27.00 (+93.41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Stephen Willey
Stifel Nicolaus
Buy
Maintained
$28.00
+100.6%
10/06/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Upgraded
$36.00
+157.9%
10/06/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$28.00
+100.6%
10/05/2026
Robert Driscoll
Wedbush
Buy
Maintained
$27.00
+93.4%
09/14/2026
Unknown Analyst
Wedbush
Buy
Maintained
$27.00
+93.4%
09/14/2026
Biren Amin
Piper Sandler
Buy
Maintained
$35.00
+150.7%
06/23/2026
Bradley Canino
Guggenheim
Buy
Maintained
$35.00
+150.7%
04/29/2026
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
04/29/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
10.84M
1.04M
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
20.35M
95.03M
17.90M
19.39M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.54M
7.31M
7.86M
8.74M
Operating expense
25.88M
102.34M
25.77M
28.13M
Total operating expenses
25.88M
102.34M
25.77M
28.13M
Operating income
-25.88M
-91.49M
-24.73M
-28.13M
Other non operating income
-
-
-
-
EBT including unusual items
-24.61M
-90.40M
-23.28M
-24.84M
EBT excluding unusual items
-24.61M
-90.40M
-23.28M
-26.61M
Income tax expense
-
2.00M
-
-
Effective tax rate
-
-2.21%
-
-
Other operating expenses
-
-
-
-
Net income
-24.61M
-92.40M
-23.28M
-24.84M
Net profit margin
-
-852.06%
-2,240.90%
-
Earnings per share
-1.37
-4.92
-0.70
-0.62
Interest and investment income
1.28M
1.10M
1.45M
1.53M
Interest expense
-
-
-
-
Net interest expenses
1.28M
1.10M
1.45M
1.53M
Depreciation and amortization charges
-
-
-
-
EBITDA
-25.86M
-91.44M
-24.66M
-28.07M
Gain or loss from assets sale
-
-
-
-1.77M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps